Pharmacokinetic Interaction between Intravenous 2′,3′-Dideoxyinosine and Pentamidine in Rats

Pharmaceutical Research

Volumn 13, Issue 4, 1996, Pages 628-632

  Yeh, Teng Kuang ^a   Kang, Hyo Jeong K ^a   Wientjes, M Guillaume ^a   Au, Jessie L S ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

2 ,3 dideoxyinosine; Pentamidine; Pharmacokinetic interaction

Indexed keywords

DIDANOSINE; PENTAMIDINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT;

ANIMALS; ANTIPROTOZOAL AGENTS; ANTIVIRAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIDANOSINE; DRUG INTERACTIONS; FEMALE; INJECTIONS, INTRAVENOUS; LIVER; MUSCLES; PANCREAS; PENTAMIDINE; RADIOIMMUNOASSAY; RATS; RATS, INBRED F344; REVERSE TRANSCRIPTASE INHIBITORS; SPLEEN; TISSUE DISTRIBUTION;

EID: 0029892019     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016018726327     Document Type: Article

References (28)

1. M. J. Shelton, A. M. O'Donnell, and G. D. Morse. Didanosine. Ann. Pharmacother. 26:660-670 (1992).
2. H. Mitsuya, R. Yarcohan, and S. Broder. Molecular targets for the AIDS therapy. Science 249:1533-1544 (1990).
3. H. Mitsuya, K. J. Weinhold, P. A. Furman, M. H. St. Clair, S. Nusinoff-Lehrmann, R. C. Gallo, D. Bolognesi, D. W. Barry, and S. Broder. 3′-Azido-3′-dideoxythymidine (BWA509U); an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. USA 82:7096-7100 (1985).
4. G. D. Morse, M. J. Shelton and A. M. O'Donnell. Comparative pharmacokinetics of antiretrovial nucleoside analogues. Clin. Pharmacokinet. 24:101-123 (1993).
5. M. Seidlin, J. S. Lambert, R. Dolia, and F. J. Valentine. Pancreatitis and pancreatic dysfunction in patients taking dideoxyinosine. AIDS 6:831-835 (1992).
6. E. Bouvet, E. Casalino, M. H. Prevost, and F. Vachon. Fatal case of 2′, 3′-dideoxyinosine-associated pancreatitis. Lancet 336:1515 (1991).
7. R. Yarchoan, H. Mitsuya, J. M. Pluda, K. S. Marczyk, R. V. Hartman, P. Brouwers, C. F. Perno, J. P. Allain, D. G. Johns, and S. Broder. The National Cancer Institute phase I study of 2′,3′-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles. Rev. Infect. Dis. 12:5522-533 (1990).
8. R. E. Chaisson, J. Keruly, D. D. Richman, and R. D. Moore. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group. Arch. Intern. Med. 152:2009-2013 (1992).
9. J. V. Fahy, D. P. Chin, L. M. Schnapp, D. J. Steiger, T. H. Schaumberg, S. M. Geaghan J. S. and P. C. Hopewell. Effect of aerosolized pentamidine prophylaxis on the clinical severity and diagnosis of Pneumocystis carinii pneumonia. Am. Rev. Respir. Dis. 146:844-848 (1992).
10. U. Balslev, and T. L. Nielsen. Adverse effects associated with intravenous pentamidine isothionate as treatment of Pneumocystis carinii pneumonia in AIDS patients. Dan. Med. Bull. 39:366-368 (1992).
11. T. E. Herchline, J. F. Plouffe, and M. F. Para. Diabetes mellitus presenting with ketoacidosis following pentamidine therapy in patients with acquired immunodeficiency syndrome. J. Infect. 22:41-44 (1991).
12. D. Boillot, P. Veld, P. Sai, G. Feutren, W. Gepts and R. Assan. Functional and morphological modifications induced in rat islets by pentamidine and other diamidines in vitro. Diabetologia 28:359-364 (1985).
13. F. T. Valentine, M. Seidlin, H. Hochster, and M. Laverty. Phase I study of 2′,3′-dideoxyinosine: experience with 19 patients at New York University medical center. Rev. Infect. Dis. 12:S534-539 (1990).
14. K. J. Connolly, J. D. Allan, H. Fitch, L. Jackson-Pope, C. McLaren, R. Canetta, and J. E. Groopman. Phase I study of 2′,3′-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine. Am. J. Med. 91:471-475 (1991).
15. H.-J. K. Kang, M. G. Wientjes, and J. L.-S. Au. Tissue pharmacokinetics of 2′,3′-dideoxyinosine in rats. Biochem. Pharmacol. 48:2109-2115 (1994).
16. V. T. DeVita, Jr. Principles of chemotherapy. V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds). Cancer: principles and practice of oncology. 3rd edition. J. B. Lippincott, Philadelphia, 1989, pp 276-300.
17. M. G. Wientjes, and J. L.-S. Au. High-performance liquid chromatographic analysis of 2′,3′-dideoxyinosine in biological samples. J. Chromatogr. 563:400-406 (1991).
18. T.-K. Yeh, J. T. Dalton, and J. L.-S. Au. High performance liquid chromatographic determination of pentamidine in plasma. J. Chromatogr. 622:255-261 (1993).
19. M. Rowland and T. N. Tozer. Clinical Pharmacokinetics. Concepts and Applications, Lea and Febiger, Philadelphia (1980).
20. D. S. Dittmer. Blood and other body fluids. Biological Handbooks, Fed. Am. Soc. Exp. Biol., Washington, D.C., 1961, pp. 394-398.
21. J. E. Conte, R. A. Upton, R. T. Phelps, C. B. Wofsy, E. Zurlinden, and E. T. Lin. Use of a specific and sensitive assay to determine pentamidine pharmacokinetics in patients with AIDS. J. Infect. Dis. 154:923-929 (1986).
22. T. R. Navin, C. M. Dickinson, S. R. Adams, M. Mayersohn, and D. D. Juranek. Effect of azotemia in dogs on the pharmacokinetics of pentamidine. J. Infect. Dis. 155:1020-1026 (1987).
23. B. J. Berger, J. E. Hall, and R. R. Tidwell. The distribution of multiple doses of pentamidine in rats. Pharmacol. Toxicol. 66:234-236 (1990).
24. P. A. Feddersen and K. Sack. Experimental studies on the nephrotoxicity of pentamidine in rats. J. Antimicrob. Chemother. 28:437-446 (1991).
25. Q. A. Bertelli, L. Giovannini, and A. Paparelli. Reduced gentamycin nephrotoxicity by fosfomycin association. Drugs Exptl. Clin. Res. 7:597-600 (1981).
26. J. Y. Chatton, A. Munfado, J. P. Chave, F. Steinhauslin, F. Roch-Ramel, M. P. Glauser and J. Biollaz. Trimethoprim, alone or in combination with sulphamethoxazone, decreases the renal excretion of zidovudine and its glucuronide. Br. J. Clin. Pharmacol. 34:551-554 (1992).
27. K. L. Goa, and D. M. Campoli-Richards. Pentamidine Isethionate: A review of its antiprotozoal activity, pharmacokinetic properties and therapeutic use in Pneumocystis carinii pneumonia. Drugs 33:242-258 (1987).
28. D. Faulds, and R. N. Brogden. Didanosine: A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. Drugs 44:94-116 (1992).